Skip to main content

Advertisement

Table 2 Analysis of survival time of Smad4-positive and Smad4-negative patients stratified with regard to tumor stage, ER-status, TβRI-status, and TβRII-status. 5-year survival rates were computed by the Kaplan-Meier estimator. Survival curves were compared by log-rank test (n = 197).

From: Smad4-expression is decreased in breast cancer tissues: a retrospective study

  5 year survival Total number Log rank test
      Number censored p
  Smad4 negative Smad4 positive Smad4 negative Smad4 positive Smad4 negative Smad4 positive  
Unstratified 92.4 74.5 44 153 35 111 0.187
WHO I 100.0* 86.7 11 24 11 19 0.135
WHO II 94.4 81.3 19 89 15 71 0.821
WHO III 92.3 54.7 13 34 9 19 0.137
WHO IV 0 20.8 1 6 0 2 0.661
WHO I/II 96.2 82.5 30 113 26 90 0.32
WHO III/IV 84.4 50.2 14 40 9 21 0.121
T1 100.0 83.7 15 37 14 29 0.209
T2 93.3 71.2 15 84 11 57 0.448
T3 87.5 63.5 8 12 5 8 0.899
T4 50.0 45.5 6 20 2 9 0.588
N0 94.1 88.1 18 64 16 52 0.425
N1 91.1 59.0 23 77 15 45 0.167
N2 50.0 52.5 2 8 1 4 0.666
N3 0 50.0 1 4 0 2 0.948
N1–3 84.3 57.9 26 89 16 51 0.227
ER negative 93.8 66.5 16 59 13 41 0.278
ER positive 91.7 78.9 28 94 22 70 0.474
TβRI negative 94.1 76.5 17 24 16 19 0.245
TβRI positive 92.3 74.1 27 129 19 92 0.523
TβRII negative 100.0 80 19 39 17 30 0.133
TβRII positive 85.9 72.8 25 114 18 81 0.806
  1. * survival times could not be computed as all cases were censored